[ad_1]
Decision considers that both drugs are already prescription drugs and have not been used in diseases and chronic patients
Anvisa suspends income withholding for ivermectin and nitazoxanide
The Collegiate Board of the National Health Surveillance Agency (Anvisa) reviewed, during a meeting held this Tuesday (1st), the requirement to retain a prescription for the drugs Ivermectin and Nitazoxanide.
Also read: Ivermectin, what science says about the ‘new chloroquine’
“In this context, it was found that the drugs Ivermectin and Nitazoxanide, at the moment, are not under the threat of a market shortage. The change was adopted with the aim of guaranteeing the population’s access to treatment for verminosis and parasitosis, which are well known and very significant, ”says the Agency.
According to Anvisa, the measure is part of the monitoring of substances subject to control due to the public health emergency due to the pandemic related to the new coronavirus (covid-19).
The decision also considers that the two drugs are already prescription drugs and have not been used in diseases and chronic patients. The measure begins to take effect after its publication in the Official Gazette of the Federation.
